| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036677563 |
| P356 | DOI | 10.1038/SJ.ONC.1207553 |
| P698 | PubMed publication ID | 15077194 |
| P5875 | ResearchGate publication ID | 8625565 |
| P50 | author | Anindita Das | Q41817668 |
| P2093 | author name string | Mariano J Scian | |
| Evie H Carchman | |||
| Sumitra Deb | |||
| Debabrita Deb | |||
| Swati Palit Deb | |||
| Katherine E R Stagliano | |||
| Michelle A Ellis | |||
| Kristopher Valerie | |||
| P2860 | cites work | The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation | Q24291244 |
| A model for p53-induced apoptosis | Q24313374 | ||
| Organization and expression of the cell cycle gene, ts11, that encodes asparagine synthetase | Q24319866 | ||
| p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation | Q24553136 | ||
| NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription | Q24600573 | ||
| Functional interaction between DP-1 and p53 | Q24648034 | ||
| Telomerase and breast cancer | Q24801314 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| WAF1, a potential mediator of p53 tumor suppression | Q27861121 | ||
| Surfing the p53 network | Q28032484 | ||
| Definition of a consensus binding site for p53 | Q28207794 | ||
| p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60 | Q28304820 | ||
| Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells | Q28577540 | ||
| p53 gene mutation: software and database | Q59526222 | ||
| Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors | Q73595318 | ||
| Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity | Q73615074 | ||
| Signaling to p53: breaking the MDM2-p53 circuit | Q77430977 | ||
| Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains | Q28609779 | ||
| IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools | Q30429006 | ||
| Molecular epidemiology of human cancer | Q33533997 | ||
| Insulin-like growth factors in human breast cancer. | Q33538445 | ||
| Diagnosis and treatment of urethral prolapse in children | Q33799343 | ||
| The p53 gene family | Q33807839 | ||
| The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth | Q34402080 | ||
| On the shoulders of giants: p63, p73 and the rise of p53. | Q34511214 | ||
| Telomere lengthening in telomerase-negative cells: the ends are coming together | Q34692124 | ||
| Telomerase as a diagnostic and therapeutic target for cancer | Q34734539 | ||
| p73: Friend or foe in tumorigenesis | Q34770297 | ||
| TP53 family members and human cancers | Q35078717 | ||
| Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. | Q35207550 | ||
| Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter | Q38288588 | ||
| Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. | Q38322063 | ||
| Identification of a novel p53 functional domain that is necessary for mediating apoptosis | Q38337319 | ||
| A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition | Q38349842 | ||
| Pharmacogenomic analysis of mechanisms mediating ethanol regulation of dopamine beta-hydroxylase | Q38352910 | ||
| Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells | Q40281014 | ||
| p53 and human cancers. | Q40648173 | ||
| How loops, beta sheets, and alpha helices help us to understand p53. | Q40694267 | ||
| Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway | Q40729397 | ||
| Role of Sp1 and Sp3 in the nutrient-regulated expression of the human asparagine synthetase gene | Q40747968 | ||
| Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants | Q40755915 | ||
| Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. | Q40790222 | ||
| DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. | Q40796673 | ||
| DNA microarrays identification of primary and secondary target genes regulated by p53. | Q40799703 | ||
| IGF-II promotes mesoderm formation | Q40842744 | ||
| Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation | Q40852695 | ||
| Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. | Q40962924 | ||
| Direct activation of TERT transcription by c-MYC. | Q40973563 | ||
| 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain | Q41023862 | ||
| SAGE transcript profiles for p53-dependent growth regulation | Q41092725 | ||
| Gain of function mutations in p53. | Q41557652 | ||
| L-asparaginase kills lymphoma cells by apoptosis | Q41579847 | ||
| Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. | Q41643433 | ||
| Linking global histone acetylation to the transcription enhancement of X-chromosomal genes in Drosophila males | Q43668372 | ||
| Overexpression of p73 causes apoptosis in vascular smooth muscle cells | Q43972822 | ||
| p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein | Q44332035 | ||
| Application of the S-score algorithm for analysis of oligonucleotide microarrays | Q44898589 | ||
| Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type I-associated leukemogenesis | Q45747438 | ||
| The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen | Q46840212 | ||
| Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation. | Q52537919 | ||
| p53 domains: identification and characterization of two autonomous DNA-binding regions. | Q52544476 | ||
| Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73 | Q57778801 | ||
| p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis | Q59526217 | ||
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4430-4443 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes | |
| P478 | volume | 23 |
| Q35804653 | Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. |
| Q37973676 | Chromosome instability and deregulated proliferation: an unavoidable duo. |
| Q33588105 | Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. |
| Q54777296 | Comparative pan-cancer DNA methylation analysis reveals cancer common and specific patterns. |
| Q35103336 | Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. |
| Q64119694 | Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer |
| Q37181510 | DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling |
| Q42819037 | Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells |
| Q38915906 | Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines |
| Q39000725 | Down-regulation of asparagine synthetase induces cell cycle arrest and inhibits cell proliferation of breast cancer |
| Q33588196 | Expression signatures of TP53 mutations in serous ovarian cancers |
| Q36415118 | Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma |
| Q36481940 | Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl |
| Q34985284 | Identification of potential synthetic lethal genes to p53 using a computational biology approach |
| Q97538360 | Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer |
| Q36468744 | Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer |
| Q53070929 | Ionizing radiation activates PERK/eIF2α/ATF4 signaling via ER stress-independent pathway in human vascular endothelial cells. |
| Q38767064 | Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells |
| Q48690318 | Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. |
| Q37352111 | Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase |
| Q30542607 | More targets, more pathways and more clues for mutant p53. |
| Q39460398 | Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. |
| Q38844605 | Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication |
| Q46709821 | Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q36993572 | Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q39297236 | Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity |
| Q24791476 | Mutant p53 proteins bind DNA in a DNA structure-selective mode |
| Q36070574 | Mutant p53: one name, many proteins |
| Q36709532 | NF-kappa B as a target for cancer therapy |
| Q41808246 | Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. |
| Q34373621 | Oncomorphic TP53 Mutations in Gynecologic Cancers Lose the Normal Protein:Protein Interactions with the microRNA Microprocessing Complex |
| Q98199317 | Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma |
| Q34651573 | Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. |
| Q38457645 | Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites |
| Q28273002 | Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 |
| Q38161342 | Role of p53 in Cell Death and Human Cancers |
| Q89956023 | TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies |
| Q34775855 | TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. |
| Q40325392 | The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. |
| Q34519833 | The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes |
| Q37225303 | The consequence of oncomorphic TP53 mutations in ovarian cancer |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q36777349 | Transcription regulation by mutant p53. |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q37660051 | Transcriptional control of the proliferation cluster by the tumor suppressor p53. |
| Q39614332 | Tumor-derived p53 mutants induce NF-kappaB2 gene expression |
| Q35086367 | Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q38296687 | Wild-type p53 and p73 negatively regulate expression of proliferation related genes |
| Q79306638 | p53 downstream target genes and tumor suppression: a classical view in evolution |
Search more.